PRESS-RELEASE filed May 12, 2026 at 16:05 ET
TELA Bio reported Q1 2026 revenue of $19.1M (+3% YoY), slightly above the $19.0M consensus, and an EPS of -$0.21 (GAAP), which is worse than the -$0.19 consensus estimate. The company reiterated full-year 2026 revenue guidance of at least 8% growth, but Q1 growth was only 3%, and net loss widened to $12.3M from $11.3M a year ago. The stock may face pressure from the EPS miss and decelerating revenue growth, partially offset by the reiterated guidance and European momentum.